Dr Lea Hachmeister
Areas of practice
Dr Lea Hachmeister is a life sciences lawyer specialising in regulatory advice on the European healthcare market and digitalisation projects. She advises pharmaceutical, medical technology and food companies, providers of digital health solutions and investors on regulatory issues such as clinical research, market entry and reimbursement channels for medicinal products and medical devices, telemedicine, strategic collaborations, and industry-specific data protection and compliance issues. Ms Hachmeister has particular expertise in cross-border projects and transactions in the healthcare and food sectors. Ms Hachmeister has gained valuable in-house experience through secondments in the pharmaceutical industry.
Vita
Dr Lea Hachmeister studied law at Philipps University in Marburg, where she also obtained an additional qualification in pharmaceutical law. After passing her first state examination, she wrote a dissertation on the topic of ‘Clinical trials with adults incapable of giving consent – Legal framework for research for the benefit of a group.’
Since March 2024, Ms. Hachmeister is author of the Brussels Report in the industry journal PharmR and a member of its editorial advisory board. Dr Hachmeister worked in the life sciences and healthcare practice of an international law firm before joining Luther in July 2025.
Honors and distinctions
- Best Lawyers 2026: Recommendation ‘Ones to Watch’ in the category ‘Health Law’
- The Legal 500 Germany: Recommendation in the category ‘Industry Focus - Health’ (2024).
Clients
- Regulatory advice on setting up a biobank
- Advice on establishing a research collaboration in the field of AI-supported precision medicine
- Representation of a pharmaceutical company in legal disputes in the field of drug pricing law
- Advice to a leading global provider of supply concepts for clinical trials
- Advising on the acquisition of a pharmaceutical company in the field of radiopharmaceuticals
- Advising on the acquisition of a medical technology company focusing on digital women's health
- Advising on the acquisition of a food company focusing on novel foods and dietary supplements
- Regulatory advice to medical technology start-ups on setting up digital platforms and digital applications
- Establishment of a telemedicine platform, advice on medical and data protection law
- Regulatory advice on the implementation of a compassionate use programme
- Regulatory advice on market entry for international healthcare companies
Publications
- Im Zweifel ein Präsentationsarzneimittel – Das Aus für stoffliche Medizinprodukte? in PharmR, Ausgabe 10/2025
- Die Dezentralisierung klinischer Arzneimittelstudien im Spannungsfeld zu Guter Klinischer Praxis und Gesundheitsdatenschutz, in PharmR, Ausgabe 3/2025
- Life Sciences Law in Germany, in Lexology In-Depth: Life Sciences Law, Ausgabe 2/2025
- Seit März 2024 Autorin des Berichts aus Brüssel der Fachzeitschrift PharmR
- Investing in Healthcare and Life Sciences: An International Guide to Regulatory and Transactional Issues Across the Sector 2023
- German Health Data Use Act – Access for Research Purposes, in the Legal Industry Review, 3. Edition 2023
- Covid-19-Pandemie beeinflusst M&A im Gesundheitsmarkt, in DeviceMed, Ausgabe 3/2022
- Klinische Forschung mit einwilligungsunfähigen Erwachsenen - Rechtliche Rahmenbedingungen einer gruppennützigen Forschung Diss., Philipps-Universität Marburg 2021
Lectures
- 25.11.2025: Datenschutzkonformer Einsatz von KI in der Pharmaindustrie I Ausschuss Klinische Forschung des Bundesverbandes der pharmazeutischen Industrie
- 19.11.2025: Was gibt es Neues - und was kommt 2026? Aktuelle europäische und nationale Entwicklungen für Arzneimittel- und Medizinproduktehersteller I Webinar
- 19.10.2025: Der Einsatz von KI in der Medizin - Chancen nutzen und rechtssicher handeln I Kongress Viszeralmedizin 2025
- 10.07.2025: KI-Verordnung & Datenschutz - Spannungsverhältnis oder Synergiepotentiale? I Ausschuss Digitale Zukunft des Bundesverbandes der pharmazeutischen Industrie.
- 26.11.2024: The EU AI Act´s impact on Pharma - Webinar
- 14.03.2024: Die Dezentralisierung klinischer Studien im Spannungsfeld zu Good Clinical Practice und Gesundheitsdatenschutz; 27. Marburger Gespräche zum Pharmarecht
Memberships
- Support Association for the Research Centre for Pharmaceutical Law
- Editorial Advisory Board of the journal PharmR
- German Legal Society for Animal Welfare Law
- Amnesty International
Senior Associate
Dr Michael Ebert
Counsel
Stuttgart
István Fancsik, LL.M. (London)
Senior Associate
Essen
Dr Hans-Peter Hufschlag
Senior Associate
Hamburg
Lutz Keller
Senior Associate
Cologne
Luisa Kramer
Associate
Hamburg
Dominik Menhaj
Senior Associate
Hamburg
Theresa Oesch
Senior Associate
Leipzig
Dr Katharina Preuss
Senior Associate
Cologne
Guido Wenzel
Partner
Hamburg
Pierre Daniel Wittmann
Senior Associate
Frankfurt a.M.
Julie Schwarz, LL.M. (Georgetown)
Associate
Kuala Lumpur
Dr Eckart Petzold
Partner
Dusseldorf
Jan Spiering, LL.M. Taxation
Associate
Hanover
Marc Theiner
Associate
Singapore
Jan Zimmer
Senior Associate
Singapore
Dr.iur. Andreas Knaul, LL.M. diap (ENA)
Berlin